LONDON, Nov. 20, 2017 (GLOBE NEWSWIRE) -- As per the report titled as “In Vitro Diagnostics (IVD) Quality Control Market–Global Opportunity Analysis and Industry Forecast (2017-2022)”, the global IVD quality control market will grow at a CAGR of 3.8% during the forecast period to reach USD 1,065.3 million by 2022. This market is driven by the increasing number of accredited clinical laboratories, growing demand for external quality assessment (EQA) support, and increasing mandates from regulatory & accreditation bodies on the use of quality controls. However, additional costs burden associated with quality controls on laboratories, unfavourable reimbursement scenario for IVD tests, and lack of mandatory regulations for clinical laboratory accreditation in many emerging countries is expected to restrain the growth of this market to a certain extent.
Based on application, this market is majorly segmented into clinical chemistry, hematology, immunoassay, molecular diagnostics, microbiology, coagulation/hemostasis, and others. The immunoassay segment accounted for the largest share of the global IVD quality controls market in 2016 and is also expected to continue its dominance during the forecast period. The large share of this segment is attributed to the higher adoption of high sensitive and cost-effective immunoassay tests for the diagnosis of increasing infectious diseases and relatively increased demand for multi-analyte immunoassay controls to ensure the accuracy & reliability of immunoassay test menus.
Request Sample Report: http://www.meticulousresearch.com/request-sample-report/?cp_id=3447
On the basis of end user, this market is majorly segmented into hospitals, clinical/ reference laboratories, research & academic institutes, and others. Hospitals segment held the largest share in the global IVD quality controls market in 2016, mainly due to the large share of diagnostics tests performed in the hospital attached laboratories and relatively higher demand for quality controls in these healthcare settings to ensure the accuracy and reliability of IVD test results of the patients.
The major players operating in the global In Vitro Diagnostics Quality Controls Market are Randox Laboratories Ltd. (U.K.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Technopath Clinical Diagnostics (Ireland), SeraCare Life Sciences Inc. (U.S.), Merck KGaA (Germany), Maine Molecular Quality Controls, Inc. (U.S.), Sero AS (Norway), Eurotrol B.V. (The Netherlands), Omega Diagnostic Group PLC (U.K.), Fortress Diagnostic Limited (U.K.), Sun Diagnostics, LLC. (U.S.), Siemens AG (Germany), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Helena Biosciences Europe (U.K.), Danaher Corporation (U.S.), Ortho Clinical Diagnostics (U.S.), ZeptoMetrix Corporation (U.S.), and Becton, Dickinson and Company (U.S.).
Browse in-depth report at http://www.meticulousresearch.com/product/ivd-in-vitro-diagnostics-quality-controls-market-2022/
AVP- Global Sales and Marketing
Direct Lines: +1-646-781-8004 (North America)
+91 744-7780008 (Asia-Pacific)